China’s Green Channel Significantly Shortened Filing Time For Start-up Hua Medicine
This article was originally published in PharmAsia News
Start-up Hua Medicine says IND filing time using China’s green channel shortened the review process at the provincial level.
You may also be interested in...
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China: An Interview With PharmAsia News (Part 2 of 2)
Swiss-headquartered Roche was the first multinational pharmaceutical outfit to establish a research and development center in China, and the company recently set up one of its PharmaPartnering groups in Shanghai. Roche's China CSO Li Chen sat down with PharmAsia News to talk about how the company is approaching R&D in the region and evolving in tandem with the pharma landscape in China. Chen is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.